Financing ·
Soligenix, Inc. filed a prospectus supplement on June 26, 2026, to increase the maximum aggregate offering amount of…
SNGXSoligenix, Inc.
Soligenix, Inc. filed a prospectus supplement on June 26, 2026, to increase the maximum aggregate offering amount of common stock issuable under its At Market Issuance Sales Agreement with Rodman & Renshaw LLC by an additional $2,500,000. The company previously sold approximately $6,234,000 of shares of common stock under the own Sales Agreement. Soligenix, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions for neglected and orphan diseases.